Radar · Oncology in New York City
Best Oncology Companies in New York City, United States
The 124 best Oncology companies in New York City, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Everest Medicines.
By Riya SenguptaFinancials
124companies tracked
$4.1Bdisclosed funding
0unicorns
83have raised
FLIAR INTELLIGENCE · ONCOLOGY × NEW YORK CITY
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
86%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
195kcombined LinkedIn audience
34%of audience held by top 3
1companies hiring publicly (12 mo)
Ranked: Best Oncology companies in New York City
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Everest Medicines Developer of drugs for the treatment of cancer | $593M | 72 mo ago | 395 | Kerry Blanchard CEO | Node.jsSvelteKitSvelte+5 | — | 3 partnerships |
| 2 | Goodhealth Bioscience Developer of antibody-based therapeutics to treat cancer | $385M | 60 mo ago | — | — | — | — | — |
| 3 | Delcath Speciality Pharmaceutical and medical device company focused on oncology 74Product top 14%Funding top 20%Fin. health top 31%Innovation top 34% All 10 signals ▾Producttop 14% Fundingtop 20% Fin. healthtop 31% Innovationtop 34% Techtop 37% Growthtop 39% Markettop 43% Moattop 47% Newstop 48% Globalbottom 44% Product: 5 distinct product lines · Company stage: Public Funding: Raised $307M across 19 rounds · 19 rounds over 24 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 74/100 | $307M | 17 mo ago | 52 | — | WordPressApple iCloud MailMicrosoft 365+26 | — | — |
| 4 | Nuvation Bio Developer of therapeutics for cancer treatment | $275M | 80 mo ago | 65 | — | WordPressMySQLMariaDB+28 | 258 patents Design and synthesis of heterocyclic small‑molecule cancer drugs targeting nuclear hormone receptors. | — |
| 5 | SpringWorks Therapeutics Developer of small molecule therapeutics for treating cancer and rare diseases | $230M | 45 mo ago | 305 305 → 368 (+21%) · sector median -20% | Saqib Islam CEO | WordPressProton MailMySQL+27 | 419 patents Small‑molecule YAP/TAZ‑TEAD inhibitors and related heterocyclic oncology therapeutics | — |
| 6 | IRX Therapeutics Developing innovative cell therapies for advanced cancer and autoimmune diseases | $190M | 105 mo ago | 29 | — | — | — | — |
| 7 | Zentalis Developer of small molecule therapeutics for cancer treatment | $147M | 73 mo ago | 168 168 → 123 (-27%) · sector median -20% | Kimberly Blackwell CEO | WebflowDrupalApple iCloud Mail+25 | — | — |
| 8 | Hibercell Developer of therapeutics for the treatment of solid and liquid cancers | $128M | 61 mo ago | 53 | — | WordPressBugHerdApple iCloud Mail+26 | 122 patents Cancer immunotherapy: GCN2 modulators, beta‑glucan/CD40 agonists, and novel crystalline drugs | — |
| 9 | Neogene Therapeutics Developer of T-cell therapy for treating cancer | $125M | 69 mo ago | 120 | Carsten Linnemann Co-Founder & CEO | Apple iCloud MailApache HTTP ServerDocuSign | — | — |
| 10 | ProCure Proton Beam Therapy. Treatment for different types of Cancerous and non-cancerous tumors through Proton… | $116M | 165 mo ago | 250 | — | WordPressMySQLPHP+36 | — | — |
| 11 | C2i Genomics Provider of liquid biopsy for post cancer surgery monitoring | $112M | 62 mo ago | 64 | Ezra Sofer Co-Founder | — | — | — |
| 12 | Flame Biosciences Manufacturer of drugs for treating inflammation | $109M | 68 mo ago | — | Charles Fisher Founder | — | — | — |
| 13 | Elevation Oncology Developer of precision medicine for the treatment of cancer | $98M | 67 mo ago | 29 | Shawn Leland Founder | WordPress Block EditorWordPressMySQL+27 | 5 patents Therapeutic anti‑ERBB3 (HER3) monoclonal antibodies for NRG1‑fusion driven cancers | — |
| 14 | Mustang Bio Developer of CAR-T cell therapy for brain cancer and acute myeloid leukemia treatment | $95M | 31 mo ago | 80 80 → 43 (-46%) · sector median -20% | Manuel Litchman CEO | WordPressPleskMySQL+19 | — | — |
| 15 | Treadwell Developer of therapeutics for cancer | $91M | 55 mo ago | 47 | Mark Bray Founder | — | — | — |
| 16 | Y-mAbs Therapeutics Provider of antibodies-based products targeting GD2 and B7H3 tumor antigens. | $90M | 102 mo ago | 100 100 → 59 (-41%) · sector median -20% | — | DrupalPHPBootstrap+24 | — | — |
| 17 | Volastra Developer of therapeutics for cancer treatment 40Funding top 24%Talent top 28%Moat top 39%Tech bottom 48% All 6 signals ▾Fundingtop 24% Talenttop 28% Moattop 39% Techbottom 48% Globalbottom 37% Marketbottom 31% Funding: Raised $87.2M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 40/100 | $87M | 9 mo ago | 21 21 → 41 (+95%) · sector median -20% | Samuel Bakhoum Co-Founder | WordPressApple iCloud MailMicrosoft 365+24 | — | 1 job opening |
| 18 | Petra Pharma Small molecules for the treatment of cancer and metabolic diseases to target cellular processes such as cell… | $76M | 74 mo ago | 8 | — | — | — | — |
| 19 | Promontory Therapeutics Developer of immunotherapeutics for the treatment of cancer | $72M | 54 mo ago | 17 17 → 11 (-35%) · sector median -20% | Matthew Price Co-Founder & COO | — | — | — |
| 20 | Checkpoint Therapeutics Developer of immunotherapy and targeted cancer treatments to improve healthcare access | $58M | 126 mo ago | 24 | — | BootstrapApache HTTP ServerjQuery+7 | — | — |
| 21 | Fortress Biotech Developing novel immunotherapy agents for cancer and inflammatory diseases | $55M | 99 mo ago | 187 | Lindsay Rosenwald CEO | BootstrapApache HTTP ServerMatomo Analytics+15 | — | — |
| 22 | Quentis Therapeutics Developer of therapies for treating cancer and neurodegenerative diseases | $51M | 90 mo ago | 4 | — | — | — | — |
| 23 | Stelexis Therapeutics Developer of small molecules to target pre‐cancerous stem cells | $43M | 89 mo ago | 7 | Patrick Doyle CEO | — | — | — |
| 24 | Provista Diagnostics Molecular oncology diagnostics company | $42M | 97 mo ago | 2 | — | — | 22 patents Cancer biomarker diagnostics for early detection of breast and ovarian cancers | — |
| 25 | Indaptus Developer of immunotherapies for oncology and infectious diseases 19Funding top 35%Moat top 39%Talent bottom 49%Growth bottom 42% All 7 signals ▾Fundingtop 35% Moattop 39% Talentbottom 49% Growthbottom 42% Globalbottom 30% Marketbottom 24% Newsbottom 23% Funding: Raised $37.9M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) Moat: Editorial + unicorn rating 6/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 19/100 | $38M | 12 mo ago | 6 | Jeffrey Meckler Chief Executive Officer | — | — | — |
| 26 | IN8Bio Provider of immune based therapies for the treatment of cancer 50Funding top 27%Patents top 32%Moat top 38%Innovation top 39% All 10 signals ▾Fundingtop 27% Patentstop 32% Moattop 38% Innovationtop 39% Techtop 41% Newstop 42% Growthtop 45% Talentbottom 41% Marketbottom 39% Globalbottom 36% Funding: Raised $35.0M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) Patents: 33 patents matched (strict assignee match) · 25 filings since 2022 vs 8 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $35M | 5 mo ago | 31 31 → 25 (-19%) · sector median -20% | William Ho Founder & CEO | DrupalPHPZURB Foundation+22 | 33 patents Engineered gamma‑delta T‑cell CAR immunotherapies for cancer treatment | — |
| 27 | RenBio Developer of antibody-based therapeutic solutions for the treatment of cancer & inflammatory diseases | $29M | 21 mo ago | 10 10 → 8 (-20%) · sector median -20% | David Ho Co-Founder | — | 11 patents Gene therapy delivery devices and plasmid expression vectors for therapeutic proteins/peptides | — |
| 28 | Bantam Pharmaceutical Pioneering mitochondrial-targeted therapeutics for hematological and solid tumors | $25M | 57 mo ago | 7 | — | — | — | — |
| 29 | BAKX Therapeutics Developer of transformative cancer therapies | $25M | 57 mo ago | 7 | Evris Gavathiotis Co-Founder | — | — | — |
| 30 | AcuamarkDx Provider of non-invasive screening test for early detection of cancer | $20M | 24 mo ago | 6 | Bernard Peperstraete Cofounder & CEO | — | — | — |
| 31 | Lucid Diagnostics Developer of diagnostic kit for oesophagal cancer | $19M | 32 mo ago | 74 74 → 115 (+55%) · sector median -20% | Lishan Aklog Md Chairman & CEO | WebflowApple iCloud MailFroala Editor+18 | — | — |
| 32 | Actinium Pharma Developer of radiation conjugates antibodies for the treatment of cancer | $18M | 69 mo ago | 22 | — | BootstrapApache HTTP ServerAmazon Web Services+9 | — | — |
| 33 | OverT Bio Developer of cell therapies to treat solid tumors | $16M | 18 mo ago | — | Neville Sanjana Co-Founder | Webflow EcommerceWebflowjQuery+7 | — | — |
| 34 | Waypoint Digital cell therapy platform for providers | $14M | 23 mo ago | 9 | David Phizicky Co-founder and CSO | — | — | — |
| 35 | Tracer Bio Developer of ultrasensitive ctDNA assay for molecular response surveillance | $10M | 18 mo ago | — | Gopal Ramachandran Co-Founder & CSO | — | — | — |
| 36 | ENB Therapeutics Small molecule inhibitors targeting a novel pathway to treat malignant melanoma | $10M | 32 mo ago | 8 | Sumayah Jamal President | — | — | — |
| 37 | Harmonic Discovery Developer of kinase inhibitor drugs for oncology | $8M | 45 mo ago | 7 | Rayees Rahman Co-Founder & CEO | — | — | — |
| 38 | Glycotest Provider of non-invasive blood tests for liver cancers and fibrosis-cirrhosis | $7M | 28 mo ago | 2 | — | — | — | — |
| 39 | Starton Developer of drug delivery solution and drugs for treating oncology | $6M | 20 mo ago | 14 | Pedro Lichtinger Chairman & CEO | WordPress Block EditorWordPressMySQL+16 | — | — |
| 40 | Aethon Therapeutics Developer of immunotherapies for cancer treatment | $6M | 21 mo ago | 7 | Benjamin Neel Co-Founder | — | — | — |
| 41 | Ancilia Developer of microbiome therapies for immunology and oncology indications 19Funding top 37%Patents top 41%Innovation bottom 49%Moat bottom 49% All 7 signals ▾Fundingtop 37% Patentstop 41% Innovationbottom 49% Moatbottom 49% Globalbottom 43% Marketbottom 20% Newsbottom 18% Funding: Raised $4.2M across 6 rounds · 6 rounds over 2 yrs (3.0/yr) Patents: 11 patents matched (strict assignee match) · 9 filings since 2022 vs 2 in 2017-21 rank vs industry peers · Fliar Intelligence Index 19/100 | $4M | 4 mo ago | 5 | — | — | 11 patents Blockchain security analytics and microbiome modulation therapeutics | — |
| 42 | Summit Biomedical Imaging Developer of diagnostic solutions for the early detection of cancer diseases | $4M | 15 mo ago | 3 | Thomas Reiner Co-Founder & Scientific Advisor | — | — | — |
| 43 | Episteme Prognostics Developer of precision therapeutics for pancreatic cancer | $4M | 37 mo ago | 2 | Surajit Dhara Founder & CEO | — | 6 patents Epigenomic profiling of chromatin accessibility using qPCR‑based array assays | — |
| 44 | Lime Therapeutics Developer of therapeutics for cancer, metabolic diseases, and neurodegenerative disorders | $3M | 26 mo ago | 2 | Daniel Heller Co-Founder | — | — | — |
| 45 | TEZCAT Laboratories Developing therapies for cancer treatment | $2M | 13 mo ago | — | Andrew Hauser Co-Founder & COO | — | — | — |
| 46 | Synthis Therapeutics Developer of therapeutics to treat cancer | $1M | 21 mo ago | 3 | Dori Karyat Founder & CEO | — | — | — |
| 47 | PAVmed Developer of medical devices and biomarkers to detect various diseases | $845K | 4 mo ago | 107 | — | WebflowjsDelivrGoogle Hosted Libraries+7 | 50 patents Minimally invasive catheter systems for fluid control and fibrous tissue division. | — |
| 48 | PyrOjas Developer of autologous whole-cell vaccine for durable cancer control | $748K | 20 mo ago | — | Archis B Founder & CEO | — | 3 patents Immunotherapy pharmaceutical compositions for cancer treatment | — |
| 49 | MiNK Therapeutics Developer of T cell therapies for cancer and other immune-mediated diseases | $306K | 13 mo ago | 37 37 → 31 (-16%) · sector median -20% | Jennifer Buell CEO | DrupalPHPBootstrap+25 | — | — |
| 50 | Humane Genomics Developer of cancer therapeutics using the oncolytic virus | $125K | 16 mo ago | 8 | Chad Moles Co-Founder & CSO | — | 10 patents Engineered oncolytic viruses and modular viral genome platforms for targeted cancer therapy | — |
Top 12 Oncology companies in New York City
#1
Public · New York City, New York · founded 2020 · 31 employees$35Mraised▾
Public · New York City, New York · founded 2020 · 31 employees
Provider of immune based therapies for the treatment of cancer. The company offers its proprietary technology and develop genetically modified gamma-delta (γδ) T cells for targeting cold, low mutation cancers cell. It offers pipeline of drug candidates which include INB-200 for glioblastoma, INB-100 for leukemia, INB-400 for solid tumors, and others.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 27%Patents
top 32%Moat
top 38%Innovation
top 39%Tech
top 41%News
top 42%Funding: Raised $35.0M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) · Last round Post IPO (Dec 2025)
Patents: 33 patents matched (strict assignee match) · 25 filings since 2022 vs 8 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 5/10 · IP moat: 33 patents · 10 curated direct competitors tracked
Audience (LinkedIn): 5k LinkedIn followers — 2.5% of this cohort's audience
Funding rounds
- Dec 2025Post IPO$20.1M
- Oct 2024Post IPO$12.4M
- Dec 2023Post IPO$14.4M
- Sep 2020Series C$35M
Founders & team
Investors
Bios Partners, Innovation Depot
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai
#2
Series B · New York City, New York · founded 2019 · 21 employees$87.2Mraised▾
Series B · New York City, New York · founded 2019 · 21 employees
Developer of therapeutics for cancer treatment. The company is developing compounds to target chromosomal instability and related pathways to inhibit genomic instability and disease progression. It also developing proprietary imaging technologies to identify chromosomal instability cancers.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 24%Talent
top 28%Moat
top 39%Tech
bottom 48%Global
bottom 37%Market
bottom 31%Funding: Raised $87.2M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) · Last round Series B (Sep 2025)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 7k LinkedIn followers — 3.4% of this cohort's audience
Hiring (LinkedIn): 5 hiring posts in 12 mo (public) · momentum -1 · hiring: Clinical Project Manager / Senior Clinical Project Manager, Senior Clinical Data Manager
Funding rounds
- Sep 2025Series B$30.1M
- May 2024Series A$15M
- Mar 2023Series A$60.2M
- Apr 2021Seed—
Founders & team
Investors
Polaris Partners, Droia, Arch Venture Partners, Vida Ventures, Catalio Capital Management, Droia Ventures
Tech stack
Anime.JsAosApple Icloud MailCloudflareCloudflare Bot ManagementCore-Js
#3
Public · New York City, New York · founded 1987 · 52 employees$306.6Mraised▾
Public · New York City, New York · founded 1987 · 52 employees
Speciality Pharmaceutical and medical device company focused on oncology. Proprietary product-Melphalan Hydrochloride Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS)-is designed to administer high dose chemotherapy to the liver, while controlling the systemic exposure to those agents. In the USA, the product is not yet approved for sale. In Europe, melphalan hydrochloride is marketed as a device under the name CHEMOSTAT delivery system for melphalan. The pipeline includes a number of clinical trials of high dose chemotherapy for liver cancers such as hepatocellular carcinoma, neuroendocrine tumor, and colorectal cancer
Fliar Intelligence Index™ 74how this company ranks against its industry peers
Product
top 14%Funding
top 20%Fin. health
top 31%Innovation
top 34%Tech
top 37%Growth
top 39%Product: 5 distinct product lines · Company stage: Public
Funding: Raised $307M across 19 rounds · 19 rounds over 24 yrs (0.8/yr) · Last round Post IPO (Dec 2024)
Fin. health: Revenue ~$85.2M (FY2024) · Net margin -4.3% · Revenue +129% YoY
Audience (LinkedIn): 9k LinkedIn followers — 4.4% of this cohort's audience
Funding rounds
- Dec 2024Post IPO$16.3M
- Mar 2024Post IPO$7M
- Mar 2023Post IPO$35M
- Dec 2022Post IPO$6.2M
Investors
Vivo Capital, Logos, BVF Partners, Rosalind Advisors, Stonepine, Serrado Capital
Tech stack
AccessibeAcquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform Launch
#4
Series B · New York City, New York · founded 2019 · 5 employees$4.2Mraised▾
Series B · New York City, New York · founded 2019 · 5 employees
Developer of microbiome therapies for immunology and oncology indications. It offers bacterial therapeutics that target the viral components of the microbiome to treat chronic diseases. The therapies are based on CRISPR technology that enhances bacterial immunity against viruses and modulates the human microbiome.
Fliar Intelligence Index™ 19how this company ranks against its industry peers
Funding
top 37%Patents
top 41%Innovation
bottom 49%Moat
bottom 49%Global
bottom 43%Market
bottom 20%Funding: Raised $4.2M across 6 rounds · 6 rounds over 2 yrs (3.0/yr) · Last round Series B (Feb 2026)
Patents: 11 patents matched (strict assignee match) · 9 filings since 2022 vs 2 in 2017-21 · Latest publication 2024
Innovation: 11 patents (top 82% of patent-holders) · 9 filings since 2022 vs 2 in 2017-21
Audience (LinkedIn): 4k LinkedIn followers
Funding rounds
- Feb 2026Series B$10.1M
- Aug 2025Grant (prize money)$274.4K
- Jul 2025Grant (prize money)$274.4K
- Sep 2024Grant (prize money)$274.4K
Investors
Safar Partners, Metaplanet, PsyMed Ventures, Zubi Capital, Spacecadet, National Science Foundation
#5
Public · New York City, New York · founded 2021 · 6 employees$37.9Mraised▾
Public · New York City, New York · founded 2021 · 6 employees
Developer of immunotherapies for oncology and infectious diseases. The lead candidate Decoy20 provides broad anti-tumor and anti-viral responses in combination for the treatment of colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin’s lymphoma.
Fliar Intelligence Index™ 19how this company ranks against its industry peers
Funding
top 35%Moat
top 39%Talent
bottom 49%Growth
bottom 42%Global
bottom 30%Market
bottom 24%Funding: Raised $37.9M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) · Last round Post IPO (Jun 2025)
Moat: Editorial + unicorn rating 6/10 · 10 curated direct competitors tracked
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 1k LinkedIn followers
Funding rounds
- Jun 2025Post IPO$5.7M
- Jan 2025Post IPO$2.2M
- Jul 2021Post IPO$30M
Founders & team
#6
Public · New York City, New York · founded 2014 · 107 employees$845Kraised▾
Public · New York City, New York · founded 2014 · 107 employees
Developer of medical devices and biomarkers to detect various diseases. The products developed by the company include "CarpX" a minimally invasive device to treat carpal tunnel syndrome, "PortIO" a novel, implantable, intraosseous vascular access device, and "DisappEAR" antimicrobial resorbable ear tubes, and many more.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers — 2.2% of this cohort's audience
Activity: 1 awards announced in 12 mo
Funding rounds
- Feb 2026Post IPO$30M
- Feb 2025Post IPO$2.4M
- Jan 2025Post IPO$2.7M
- Sep 2024Grant (prize money)$892.1K
Investors
HHS, WI Harper Group
Tech stack
CloudflareGoogle Font ApiGoogle Hosted LibrariesGoogle Tag ManagerHstsHttp/3
#7
Series A · New York City, New York · founded 2016 · 10 employees$29.2Mraised▾
Series A · New York City, New York · founded 2016 · 10 employees
Developer of antibody-based therapeutic solutions for the treatment of cancer & inflammatory diseases. The company's proprietary MYO technology involves in the development of antibody therapeutic that helps in treating rare diseases, viral infections, autoimmune diseases, and more by using DNA blueprint & antibody factory.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Funding rounds
- Aug 2024Series A$5.2M
- Jan 2021Series A$24M
- Jul 2016Grant (prize money)$3.4M
Founders & team
Investors
Ruentex Industries, Military Health
Tech stack
WordpressMysqlPhpWp RocketNginxJquery Migrate
#8
Seed · New York City, New York · founded 2022$16Mraised▾
Seed · New York City, New York · founded 2022
Developer of cell therapies to treat solid tumors. The company is pioneering pooled functional screening and synthetic genomics platforms Over Target and OverTune to develop next-generation engineered immune cells to target cancer cells.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Funding rounds
- Nov 2024Grant (prize money)$120K
- May 2024Seed$16M
Founders & team
Investors
Artis Ventures, Wing Venture Capital, Fusion Fund, OMX Ventures, Alexandria, Gaingels
Tech stack
CloudflareGoogle AnalyticsGoogle WorkspaceHstsHttp/3Jquery
#9
Funding Raised · New York City, New York · founded 2016 · 3 employees$4.1Mraised▾
Funding Raised · New York City, New York · founded 2016 · 3 employees
Developer of diagnostic solutions for the early detection of cancer diseases. The company has developed a fluorescent small molecule, PARPi-FL by using propitiatory technology that helps to detect early stage of PARP1, which is common in certain cancers. It also helps in diagnosing In vivo oral cancer, Ex vivo cervical cancer, Ex vivo esophageal cancer, Ex vivo breast cancer, and more.
Funding rounds
- Mar 2025Grant (prize money)$1.8M
- Sep 2020Grant (prize money)$1.8M
- Mar 2019Grant (prize money)$300K
- Sep 2018Grant (prize money)$299.9K
Founders & team
Investors
HHS, Harlem Biospace
#10
Series A · New York City, New York · founded 2021$10Mraised▾
Series A · New York City, New York · founded 2021
Developer of ultrasensitive ctDNA assay for molecular response surveillance. It offers tumor-informed personalization with digital polymerase chain reaction technology that helps simplify biological analyses and enables research. It focuses on high-performance computing and bioinformatics to improve the efficiency and accuracy of biological research and analysis.
Funding rounds
- Dec 2024Series A$10M
Founders & team
Investors
GKCC, Exor, Great Oaks Venture Capital, Caffeinated Capital, Pareto, Impatient
#11
Seed · New York City, New York · founded 2017 · 14 employees$6.5Mraised▾
Seed · New York City, New York · founded 2017 · 14 employees
Developer of drug delivery solutions and drugs for treating oncology. The pipeline products include Lenalidomide for treating chronic lymphocytic leukemia, multiple myeloma, Olanzapine for PARPi induced nausea, and vomiting. Transdermal delivery systems use an adhesive patch to deliver medicine through the skin. The delivery is a controlled, sustained release over multiple days.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 1k LinkedIn followers
Funding rounds
- Oct 2024Seed$2.1M
- Oct 2023Seed$970.9K
- Jan 2023Seed$1M
- Feb 2022Seed$1.1M
Founders & team
Investors
LOVE Pharma, Goldfingr
Tech stack
CloudflareCloudflare Bot ManagementCore-JsGoogle WorkspaceGravity FormsGsap
#12
Funding Raised · New York City, New York · founded 2018$2.2Mraised▾
Funding Raised · New York City, New York · founded 2018
TEZCAT is developing therapies for cancer treatment. It is focusing on colorectal cancer and its technology block cancer processes such as nutrient scavenging via macropinocytosis and YAPL signaling.
Funding rounds
- May 2025Grant (prize money)$2.2M
Founders & team
Investors
HHS, Design Technologies
Funding & investor landscape
$4.1Btotal disclosed funding
81companies funded
233disclosed rounds
0rounds last 90 days
Most active investors
Notable founders
William Ho
Founder & CEO · IN8Bio
Samuel Bakhoum
Co-Founder · Volastra
Olivier Elemento
Co-Founder · Volastra
Jeffrey Meckler
Chief Executive Officer · Indaptus
David Ho
Co-Founder · RenBio
Yaoxing Huang
Co-Founder · RenBio
Neville Sanjana
Co-Founder · OverT Bio
Mat Legut
Co-Founder & CEO · OverT Bio
Thomas Reiner
Co-Founder & Scientific Advisor · Summit Biomedical Imaging
Christian Brand
Co-Founder & Chief Scientific Officer · Summit Biomedical Imaging
Gopal Ramachandran
Co-Founder & CSO · Tracer Bio
Mark Kaganovich
Founder & CEO · Tracer Bio
Prism market signals · United States · country-scoped Prism corpus, 1,572,524 docs
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Oncology & Cancer Therapeutics is moving in the United States
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 12,968 United States-affiliated papers.
research sentiment over time
200820172026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 52% → 67% across 2008–2026.
top research entities
- Harvard University573
- The University of Texas MD Anderson Cancer Center559
- Dana-Farber Cancer Institute413
- Johns Hopkins University356
- Cornell University352
leading researchers
Yang Liu · Yu Zhang · Hinda Najem · Wenxue Ma · Yan-Ruide Li · Murad Novruzov · Waseem Ullah Khan · Ullah Khan Inam
▲
Breakthroughs4,499 · 35%
▲ 32%→35% share
▲1.1× share momentum0 median citations90% since 2021mostly methods-led
Tumor microenvironment research is surging — US breakthrough papers rose from 124 to 1,921.
rising sub-themes (early→recent)
- Tumor microenvironment124→1921
- Immune system80→1464
- Immunotherapy66→1342
- Cancer research197→1345
- Cancer immunotherapy35→714
Newly emergingFlow cytometry 0→48 · Gene 0→45 · Hepatocellular carcinoma 0→42
Landmark Cancer immunotherapy using checkpoint blockade · 6,497 cites
◆
Advancements5,898 · 45%
▲ 44%→46% share
▲1.0× share momentum1 median citations89% since 2021mostly empirical
Cancer immunotherapy advancements are intensifying — US institutional papers grew from 73 to 718.
rising sub-themes (early→recent)
- Tumor microenvironment212→2712
- Immune system142→2161
- Immunotherapy146→1778
- Cancer research238→1815
- Cancer immunotherapy73→718
Newly emergingBiomarker 0→106 · Epigenetics 0→82 · Gene 0→54
Landmark The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression · 4,937 cites
▼
Concerns1,469 · 11%
▼ 13%→11% share
▼0.8× share momentum3 median citations85% since 2021mostly reviews
Immunotherapy safety concerns are escalating — related concern papers jumped from 42 to 624.
rising sub-themes (early→recent)
- Immunotherapy42→624
- Tumor microenvironment65→585
- Immune system31→529
- Cancer immunotherapy27→298
- Cancer research49→277
Newly emergingOvarian cancer 0→30 · Immunogenicity 0→27 · Transcriptome 0→26
Landmark A framework for advancing our understanding of cancer-associated fibroblasts · 3,630 cites
RESEARCH HOTSPOTS · United States
Where oncology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston1020 · +0.56
New York829 · +0.56
SF Bay Area480 · +0.57
Chicago409 · +0.54
Philadelphia355 · +0.57
Los Angeles275 · +0.59
San Diego274 · +0.59
Pittsburgh235 · +0.55
Ann Arbor223 · +0.63
Atlanta204 · +0.54
PATENT SIGNAL · United States
Who's filing oncology patents in the United States
United States oncology patent filing is accelerating — 2,574 filings from 797 assignees (2016–2025), led by Bristol Myers Squibb, IO Therapeutics, UNIV California; annual filings 108→277.
2,574 filings797 assigneespeak 362/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Bristol Myers Squibb105
- IO Therapeutics91
- UNIV California88
- DANA Farber Cancer INST87
- Memorial Sloan Kettering Cancer 74
- Baylor College Medicine63
- UNIV Texas61
- Massachusetts INST Technology47
Common questions
How many Oncology companies are there in New York City, United States?
Radar tracks 124 indexable Oncology companies headquartered in New York City, United States that meet our profile-completeness bar.
What is the total funding raised by Oncology companies in New York City, United States?
The Oncology companies in New York City, United States on this list have raised a combined $4.1B in disclosed equity funding across 81 funded companies.
Which is the highest-funded Oncology company in New York City, United States?
Everest Medicines is the highest-funded Oncology company in New York City, United States, with $593M in disclosed equity funding.
How many Oncology companies in New York City, United States are funded?
81 of the 124 Oncology companies in New York City, United States on this list have disclosed at least one equity funding round.
How many Oncology unicorns are there in New York City, United States?
None of the Oncology companies in New York City, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in New York City, United States Oncology companies?
The most active investors in New York City, United States Oncology companies on this list include HHS, Design Technologies, Alexandria, Boxer Capital, Arch Venture Partners.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.